Robert Tokarek, MD
Dermatology · Warminster, PANPI 1083619407
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,649 of the $157,688 with a category attached, or 80.3%. 39 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 54.8% of the total. Reporting peaked in 2019 at $50,661 and has fallen 77.5% since, to $11,395 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,196 payments — averaging $131.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$86K
- Johnson & Johnson$41K
- Novartis$9K
- Galderma Laboratories, L.p.$7K
- Amgen$3K
- AbbVie$2K
- plus $9K from 33 others
What the payments were for
- Consulting fees$2,2501%
- Speaking & faculty fees$126,64980%
- Travel & lodging$6,2874%
- Food & beverage$22,48714%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,688 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $49,857 |
| Tacrolimus | 63 | $4,025 |
| Clobetasol Propionate | 120 | $3,634 |
| Fluorouracil | 44 | $2,561 |
| Tretinoin | 42 | $2,315 |
| Triamcinolone Acetonide | 177 | $2,029 |
| Metronidazole | 25 | $1,552 |
| Ciclopirox | 16 | $1,340 |
| Betamethasone Dipropionate | 29 | $1,234 |
| Ketoconazole | 68 | $1,150 |
| Minoxidil | 118 | $1,103 |
| ValacyclovirValacyclovir Hcl | 15 | $993 |
| Doxycycline Hyclate | 55 | $941 |
| Clindamycin Phosphate | 23 | $823 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 29 | $799 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Warminster
- Scott GottliebExton$2.1M
- Douglas KressWexford$2M
- Stephen HessPhiladelphia$1.7M
- Adel HaqueYardley$1M
- Joel GelfandPhiladelphia$649K
- Neil NirenPittsburgh$574K
- Victoria WerthPhiladelphia$547K
- Mark SeralyMc Murray$545K
- Laura FerrisPittsburgh$502K
- Oleg AkilovPittsburgh$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.